title: Evaluation of serum prostate-specific antigen levels after postoperative radiation therapy for pathologic stage T3, N0 prostate cancer.
abstract: OBJECTIVE
  To analyze freedom from progression of serum prostate-specific antigen (PSA) levels in patients who have received radiation therapy after radical prostatectomy for pathologic stage T3, N0 prostate cancer.
  
  
  METHODS
  We assessed the freedom from PSA progression after postoperative radiation therapy and its relationship to several potential prognostic factors during a median follow- up of 43 months.
  
  
  METHODS
  Thirty Mayo patients received postoperative radiation therapy for pathologic stage T3, N0 prostate cancer between January 1988 and April 1993. Radiation therapy was initiated within 6 months after prostatectomy. Radiation doses ranged from 60 to 67 Gy.
  
  
  RESULTS
  "Freedom from PSA failure" was defined as the actuarial risk of maintaining a serum PSA level at 0.3 ng/mL or less. The freedom from failure rate was 66% at 3 and 4 years. Prognostic factors significantly associated with an improved freedom from failure were a pre-radiation PSA level of 1.0 ng/mL or less and no seminal vesicle involvement. A trend toward an improved freedom from failure was noted in patients with low-grade (1 and 2) tumors in comparison with high-grade (3 and 4) tumors. Treatment-related morbidity was minimal.
  
  
  CONCLUSIONS
  Radiation therapy after radical prostatectomy for pathologic stage T3, N0 prostate cancer seems to provide an improved freedom from PSA failure in comparison with that noted in other series of similar patients treated with radical prostatectomy only.
authors.affiliation: Department of Radiation Oncology, Mayo Clinic Jacksonville, Jacksonville, Florida 32224, USA.
authors.forename: S J
authors.initials: SJ
authors.lastname: Buskirk
authors.forename: S E
authors.initials: SE
authors.lastname: Schild
authors.forename: E D
authors.initials: ED
authors.lastname: Durr
authors.forename: J S
authors.initials: JS
authors.lastname: Robinow
authors.forename: F F
authors.initials: FF
authors.lastname: Bock
authors.forename: J T
authors.initials: JT
authors.lastname: Wolfe
authors.forename: K M
authors.initials: KM
authors.lastname: Tomera
authors.forename: R G
authors.initials: RG
authors.lastname: Ferrigni
mesh_terms: D000368:Aged; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood* / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D011879:Radiotherapy Dosage
chemical_list: D017430:Prostate-Specific Antigen